Dr. Thomas E. Keane presented “Vitamin D and Prostate Cancer” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Keywords: prostate cancer, vitamin D
How to cite: Keane, Thomas E. “Vitamin D and Prostate Cancer” Grand Rounds in Urology. October 14-16, 2016. Accessed Dec 2024. https://grandroundsinurology.com/vitamin-d-prostate-cancer.
This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
ABOUT THE AUTHOR
Thomas E. Keane, MD, is Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers.
An avid researcher, Dr. Keane has served as principal investigator or co-investigator on more than 20 major clinical and preclinical studies. Much of his work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate the efficacy of new therapies as they relate to GU malignancies with particular reference to cytotoxic agents, sphingolipids, and boron-containing compounds. He holds a United States patent for sphingolipid derivatives and their use.
Dr. Keane’s research has led to publication of more than 100 articles peer-reviewed in such journals as The Journal of Urology, Urologic Oncology, and the Journal of Vascular Surgery. He provides editorial services to publications ranging from Urology to the International Journal of Cancer and is co-editor of the text Glenn’s Urologic Surgery, 6th, 7th, and 8th Editions. He is an accomplished speaker, having delivered many presentations to professional societies and symposia throughout the United States and abroad.
